Seagen phase 3 trial of tukysa® (tucatinib) in combination with antibody-drug conjugate ado-trastuzumab emtansine meets primary endpoint of progression-free survival in patients with previously treated her2-positive metastatic breast cancer

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced that the phase 3 her2climb-02 clinical trial of tukysa® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (kadcyla®) met its primary endpoint of progression-free survival (pfs). patients in the trial had unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (her2-positive) breast cancer and had received previous treatment with a taxane and trast.
SGEN Ratings Summary
SGEN Quant Ranking